Methods and compositions for treating inflammatory and immunological disorders

Abstract

The present invention provides a method for treating, preventing, or managing local inflammatory symptoms, including symptoms associated with acute or chronic inflammation, and particularly for conditions that are characterized by an underlying immunological disease or condition. The invention further provides methods for controlling inflammatory processes relating to cancer and the microbial flora.

1 . A method for treating or preventing inflammation local inflammatory symptoms in a patient having an underlying immunological or inflammatory disorder, the method comprising: administering a hypochlorous acid composition to an area affected by local inflammation, wherein the hypochlorous acid composition has from 100 to 5000 ppm of available free chlorine. 
     
     
         2 . The method of  claim 1 , wherein the immunological disorder is characterized by one or more of type I hypersensitivity, type II hypersensitivity, type III hypersensitivity, and type IV hypersensitivity. 
     
     
         3 . The method of  claim 1 , wherein the underlying immunological disorder is an autoimmune condition. 
     
     
         4 . The method of any one of  claims 1  to  3 , wherein the underlying immunological condition is systemic lupus erythematosus, psoriasis, atopic dermatitis, rheumatoid arthritis, celiac disease, Crohn's disease, ulcerative colitis, vasculitis, thyroiditis, severe asthma, diabetes mellitus, hyper immunoglobulin E syndrome, dermatomyositis, or multiple sclerosis. 
     
     
         5 . The method of any one of  claims 1  to  3 , wherein the underlying immunological or inflammatory disorder is eosinophilia, drug allergy, food allergy, hemolytic anemia, myasthenia gravis, systemic vasculitis, diabetes mellitus, multiple sclerosis (MS), fibromyalgia, myelitis, peripheral neuropathy, Parkinson's Disease, hepatitis, renal failure, pancreatitis, thyroiditis, graft versus host disease, chronic transplant rejection, Hidradenitis suppurativa, adult onset Still's disease, systemic onset juvenile idiopathic arthritis (SJIA) Schnitzler syndrome, Behcet's disease, SAPHO syndrome, macrophage activation syndrome, Familial Mediterranean Fever (FMF), cryopyrin-associated periodic syndrome (CAPS), TNF receptor associated periodic syndrome (TRAPS), Hyper-IgD syndrome, periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA), deficiency of interleukin-1 (IL-1) receptor antagonist (DIRA), Giant cell arteritis, amyloidosis, recurrent pericarditis, neuromyelitis optica, amyotrophic lateral sclerosis, gout, glomerulonephritis, myeloma, Netherton Syndrome, Ichthyosis, and Epidermolysis Bullosa. 
     
     
         6 . The method of any one of  claims 1  to  5 , wherein the local inflammatory symptoms include one or more of conjunctivitis, dry eye, ocular itch, uveitis, wet or dry AMD, sinusitis, rhinorrhea or nasal congestion, stomatitis, pharyngitis, gingivitis, xerostomia, airway hyper responsiveness, skin or mucosal sores or ulcers, urticaria, blisters and/or skin rash or lesions. 
     
     
         7 . The method of any one of  claims 1  to  6 , wherein the local inflammatory symptoms affect one or more of skin, eyes, nose, sinus cavity, ears, mouth or throat. 
     
     
         8 . The method of any one of  claims 1  to  6 , wherein the local inflammatory symptoms affect one or more of skin, colon, lungs, urinary tract, vagina, skeletal muscle, ligaments, tendons, joint space, bone, peritoneum, kidney, liver, pancreas, and vasculature. 
     
     
         9 . The method of any one of  claims 1  to  8 , wherein the hypochlorous acid composition is administered from 1 to 10 times per day. 
     
     
         10 . The method of  claim 9 , wherein the hypochlorous acid composition is administered from 1 to 4 times per day. 
     
     
         11 . A method for treating an immunological or inflammatory disorder, comprising, administering a hypochlorous acid composition to the patient, the immunological or inflammatory disorder being selected from: eosinophilia, drug allergy, food allergy, hemolytic anemia, angioedema, myasthenia gravis, Grave's Disease, Goodpasture's Syndrome, Farmer's Lung, asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis, systemic vasculitis, diabetes mellitus, multiple sclerosis (MS), myelitis, peripheral neuropathy, Parkinson's Disease, hepatitis, osteomyelitis, renal failure, pancreatitis, thyroiditis, graft versus host disease, chronic transplant rejection, Hidradenitis suppurativa, adult onset Still's disease, systemic onset juvenile idiopathic arthritis (SJIA) Schnitzler syndrome, Behcet's disease, SAPHO syndrome, macrophage activation syndrome, Familial Mediterranean Fever (FMF), cryopyrin-associated periodic syndrome (CAPS), TNF receptor associated periodic syndrome (TRAPS), Hyper-IgD syndrome, Hyper-IgE syndrome, periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA), deficiency of interleukin-1 (IL-1) receptor antagonist (DIRA), Giant cell arteritis, amyloidosis, recurrent pericarditis, neuromyelitis optica, amyotrophic lateral sclerosis, gout, glomerulonephritis, Netherton Syndrome, Ichthyosis, Epidermylosis Bullosa, or myeloma. 
     
     
         12 . The method of  claim 11 , wherein a hypochlorous acid composition is administered to one or more of skin, colon, lungs, urinary tract, vagina, skeletal muscle, ligaments, tendons, joints or joint space, bone, peritoneum, kidney, liver, pancreas, and vasculature. 
     
     
         13 . The method of  claim 11 , wherein the hypochlorous acid composition is administered to the skin, eyes, nasal passages, or by injection. 
     
     
         14 . A method for treating a condition selected from allergic asthma, occupational asthma, bronchitis, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis, Goodpasture Syndrome, or Farmer's Lung; comprising, administering a hypochlorous acid composition to the lungs, the hypochlorous acid composition having from 100 to 5000 ppm of available free chlorine. 
     
     
         15 . A method for treating a condition selected from contact dermatitis, radiation dermatitis, ageing skin, sunburn, angioedema, urticaria, Systemic lupus erythematosus, sarcoidosis, rosasea, dermatitis herpetiformis, Netherton Syndrome, Ichthyosis, Epidermylosis Bullosa, or cutaneous vasculitis, and hemorrhoids; wherein the hypochlorous acid composition is administered to affected portions of the skin as a hydrogel having from 100 to 5000 ppm of available free chlorine. 
     
     
         16 . A method for treating a patient having cancer, comprising, administering a hypochlorous acid composition to the patient, wherein the hypochlorous acid composition has from 100 to 5000 ppm of available free chlorine. 
     
     
         17 . The method of  claim 16 , wherein the hypochlorous acid composition slows or inhibits the progression or metastasis of the cancer. 
     
     
         18 . The method of  claim 16  or  17 , wherein the hypochlorous acid composition reduces damage to, or lesions in, one or more of mucosa, skin, and gastrointestinal tract, which results from one or more or of chemotherapy or radiation therapy. 
     
     
         19 . The method of any one of  claims 16  to  18 , wherein the cancer is stage I or stage II cancer. 
     
     
         20 . The method of any one of  claims 16  to  18 , wherein the cancer is stage III or stage IV. 
     
     
         21 . The method of any one of  claims 16  to  20 , wherein the cancer is basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain and central nervous system cancer, breast cancer, cancer of the peritoneum, cervical cancer, choriocarcinoma, colon and rectum cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, cancer of the head and neck, gastric or intestinal cancer, glioblastoma, hepatic carcinoma, hepatoma, intra-epithelial neoplasm, kidney or renal cancer, larynx cancer, leukemia, liver cancer, lung cancer, melanoma, myeloma, neuroblastoma, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, salivary gland carcinoma, sarcoma, skin cancer, squamous cell cancer, testicular cancer, thyroid cancer, uterine or endometrial cancer, cancer of the urinary system, vulval cancer, and lymphoma. 
     
     
         22 . The method of any one of  claims 16  to  20 , wherein the cancer is skin cancer, cutaneous melanoma, breast cancer, colon cancer, lung cancer, testicular cancer, cervical cancer, lymphoma, parathyroid cancer, penile cancer, rectal cancer, small intestine cancer, thyroid cancer, uterine cancer, Hodgkin's lymphoma, lip and oral cancer, leukemia or multiple myeloma. 
     
     
         23 . The method of  claim 22 , wherein the cancer is a cutaneous cancer. 
     
     
         24 . The method of  claim 22 , wherein the cancer is breast cancer. 
     
     
         25 . The method of  claim 22 , wherein the cancer is a cancer of the mouth, throat, or sinus. 
     
     
         26 . The method of  claim 22 , wherein the cancer is lung cancer. 
     
     
         27 . The method of any one of  claims 16  to  26 , wherein the hypochlorous acid is administered for at least about 2 months. 
     
     
         28 . The method of any one of  claims 16  to  27 , wherein the hypochlorous acid composition is administered directly to a tumor. 
     
     
         29 . The method of any one of  claims 16  to  27 , wherein the hypochlorous acid composition is administered topically. 
     
     
         30 . A method for normalizing the microbial flora in a patient with an inflammatory condition, comprising administering a hypochlorous acid composition to the patient, wherein the hypochlorous acid composition has from 100 to 5000 ppm of available free chlorine. 
     
     
         31 . The method of  claim 30 , wherein the hypochlorous acid composition is applied at least once per day for at least one week, or optionally at least one month. 
     
     
         32 . The method of  claim 30 , wherein normalization of the microbial flora of a tissue is determined by rRNA gene sequencing. 
     
     
         33 . The method of any one of  claims 30  to  32 , wherein the hypochlorous acid composition is applied to the skin, oral or nasal mucosa, gastrointestinal tract, or urogenital system.